NewcelX Ltd.
NCELHealthcare|Biotechnology|CH
$2.72
-0.17 (-5.73%)
DCF Value
$0.18
Graham Number
$2.39
Cash / Share
$0.12
Financials
Financial Snapshot
Market Cap
$1.2M
Enterprise Value
$908.0K
Revenue (TTM)
$0.00
Net Income (TTM)
-$720.1K
Cash & Investments
$710.0K
Net Cash
$318.0K
Free Cash Flow (TTM)
-$7.7M
Operating CF (TTM)
-$7.7M
Debt/Equity
0.06
Cash Runway & Burn Rate
Cash on Hand
$710.0K
Quarterly Burn
$1.9M
Monthly Burn
$640.4K
Est. Runway
~0.4 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.2M | $6.7K | $220.3K | $93.7K | $5.4M | $8.9M | $897.7K | $1.7M | $2.2M | $710.0K | |
| Operating Cash Flow | -$5.4M | -$2.7M | -$190.0K | -$729.4K | -$14.9M | -$13.9M | -$9.7M | -$4.3M | -$2.8M | -$7.7M | |
| Free Cash Flow | -$5.4M | -$2.7M | -$190.0K | -$729.4K | -$15.0M | -$13.9M | -$9.7M | -$4.3M | -$2.8M | -$7.7M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$4.00 | -$39.6K | $0.00 | -$4.00 | -$3.9K | -$8.0K | -$3.9K | |
| Financing Cash Flow | $6.7M | $557.9K | $407.5K | $503.5K | $20.3M | $17.4M | $1.6M | $5.0M | $2.6M | $8.7M |
R&D Spending
R&D (TTM)
$1.9M
R&D Intensity
—
R&D Growth vs Prior
+72.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $4.3M | $708.45 | $1.7M | $99.6K | $5.9M | $9.0M | $5.9M | $422.1K | $1.1M | $1.9M | |
| SG&A | $1.4M | $2.7K | $2.5M | $2.2M | $5.9M | $6.5M | $5.9M | $3.2M | $1.3M | $5.3M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $10.1K | $11.4K | $11.4K | $3.3K | $0.00 | $22.6K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$10.1K | -$11.4K | -$11.4K | -$3.3K | $0.00 | -$22.6K | |
| R&D | $4.3M | $708.45 | $1.7M | $99.6K | $5.9M | $9.0M | $5.9M | $422.1K | $1.1M | $1.9M | |
| SG&A | $1.4M | $2.7K | $2.5M | $2.2M | $5.9M | $6.5M | $5.9M | $3.2M | $1.3M | $5.3M | |
| Operating Income | -$5.8M | -$3.4K | -$4.2M | -$2.3M | -$11.9M | -$15.5M | -$11.8M | -$4.4M | -$2.5M | -$11.0M | |
| Interest Expense | $890.4K | $1.1K | $819.7K | $233.7K | $68.1K | $100.9K | $145.2K | $150.0K | $6.0M | $5.8M | |
| Pretax Income | -$6.7M | -$5.1K | -$5.4M | -$2.9M | -$11.9M | -$16.5M | -$12.2M | -$2.0M | -$8.3M | -$662.7K | |
| Net Income | -$6.7M | -$5.1K | -$5.4M | -$2.9M | -$11.9M | -$16.5M | -$12.2M | -$2.0M | -$8.3M | -$720.1K | |
| EPS (Diluted) | -5.70 | -329.90 | -4.90 | -5.90 | -8.10 | -8.40 | -3.20 | -26.30 | -2.16 | -20.07 | |
| EBITDA | -$5.8M | -$3.3K | -$4.6M | $69.6M | -$11.9M | -$15.5M | -$11.8M | -$3.6M | -$2.2M | -$7.6M | |
| Shares Out. (M) | 1.18 | 0.00 | 1.11 | 0.48 | 1.47 | 1.97 | 3.82 | 0.15 | 3.84 | 5.86 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.2M | $6.7K | $220.3K | $93.7K | $5.4M | $8.9M | $897.7K | $1.7M | $2.2M | $710.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.3M | $90.2K | $381.7K | $196.7K | $5.7M | $9.2M | $1.8M | $2.2M | $3.2M | $1.2M | |
| Total Assets | $2.3M | $145.6K | $696.4K | $1.2M | $5.8M | $9.3M | $1.8M | $2.2M | $11.4M | $9.7M | |
| Total Current Liabilities | $990.0K | $2.4M | $4.0M | $7.2M | $2.4M | $3.4M | $7.9M | $826.8K | $4.2M | $3.7M | |
| Long-Term Debt | $8.9M | $6.4M | $152.1K | $313.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $10.0M | $9.0M | $6.9M | $10.2M | $5.2M | $6.0M | $10.7M | $826.8K | $4.2M | $3.7M | |
| Stockholders' Equity | -$7.7M | -$8.8M | -$6.2M | -$9.0M | $542.4K | $3.3M | -$8.8M | $1.4M | $7.3M | $6.0M | |
| Retained Earnings | -$16.3M | -$21.5M | -$26.9M | -$29.8M | -$41.7M | -$58.2M | -$70.4M | -$74.4M | -$84.9M | -$90.5M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.4M | -$2.7M | -$190.0K | -$729.4K | -$14.9M | -$13.9M | -$9.7M | -$4.3M | -$2.8M | -$7.7M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$4.00 | -$39.6K | $0.00 | -$4.00 | -$3.9K | -$8.0K | -$3.9K | |
| Free Cash Flow | -$5.4M | -$2.7M | -$190.0K | -$729.4K | -$15.0M | -$13.9M | -$9.7M | -$4.3M | -$2.8M | -$7.7M | |
| Investing Cash Flow | $0.00 | $0.00 | -$217.3K | $225.6K | -$39.6K | -$3.5M | $0.00 | -$3.9K | $1.7M | -$2.2K | |
| Financing Cash Flow | $6.7M | $557.9K | $407.5K | $503.5K | $20.3M | $17.4M | $1.6M | $5.0M | $2.6M | $8.7M | |
| Issuance of Stock | $3.3M | $0.00 | $0.00 | $0.00 | $14.6M | $9.2M | $0.00 | $5.3M | $2.3M | $8.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $3.5M | $0.00 | $154.9K | $1.2M | -$2.1M | $825.8K | $1.6M | $0.00 | $290.0K | $194.7K | |
| Stock Based Comp. | $77.91 | $0.00 | $0.00 | $0.00 | $0.00 | $22.7K | $164.9K | $125.6K | $765.0K | $67.3K | |
| Net Change in Cash | $1.3M | -$2.2M | $213.6K | -$126.6K | $5.3M | $3.5M | -$8.1M | $767.7K | $1.6M | $156.9K |
Dilution Tracker
Shares outstanding grew 697.6% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+697.6%
Stock Issuance (TTM)
$8.5M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.18 | 0.00 | 1.11 | 0.48 | 1.47 | 1.97 | 3.82 | 0.15 | 3.84 | 5.86 | |
| Change vs Prior % | — | -100.0% | 6963537.5% | -56.7% | 206.0% | 33.5% | 94.0% | -96.0% | 2390.8% | 52.4% | |
| Stock Issuance | $3.3M | $0.00 | $0.00 | $0.00 | $14.6M | $9.2M | $0.00 | $5.3M | $2.3M | $8.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $77.91 | $0.00 | $0.00 | $0.00 | $0.00 | $22.7K | $164.9K | $125.6K | $765.0K | $67.3K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 86.3% | 0.1% | 88.3% | 31.9% | -2202.5% | -502.8% | 137.8% | -140.8% | -114.5% | 21.8% | |
| ROA % | -290.9% | -3.5% | -782.2% | -236.2% | -207.2% | -177.8% | -659.1% | -88.7% | -72.5% | 14.9% | |
| ROIC % | -443.8% | 0.2% | 158.5% | 54.5% | -352.9% | -261.7% | 266.0% | -311.5% | -32.5% | -103.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -13.5% | 0.0% | 70.9% | 100.0% | |
| Operating Income | 0.0% | 99.9% | -121593.5% | 45.2% | -415.8% | -30.5% | 23.7% | 62.9% | 43.5% | |
| Net Income | 0.0% | 99.9% | -105736.3% | 47.5% | -317.5% | -38.1% | 26.2% | 83.7% | -319.0% | |
| EPS (Diluted) | 0.0% | -5687.7% | 98.5% | -20.4% | -37.3% | -3.7% | 61.9% | -721.9% | 91.8% | |
| Operating Cash Flow | 0.0% | 49.7% | 93.0% | -283.9% | -1947.8% | 7.1% | 30.2% | 55.9% | 35.2% | |
| Free Cash Flow | 0.0% | 49.7% | 93.0% | -283.9% | -1953.2% | 7.3% | 30.2% | 55.9% | 35.1% | |
| R&D Expense | 0.0% | -100.0% | 240157.6% | -94.1% | 5844.4% | 51.6% | -34.2% | -92.9% | 166.8% | |
| SG&A Expense | 0.0% | -99.8% | 90942.1% | -11.8% | 169.6% | 9.5% | -9.2% | -45.5% | -58.1% | |
| Total Assets | 0.0% | -93.6% | 378.2% | 74.0% | 375.8% | 60.9% | -80.1% | 20.9% | 412.5% | |
| Book Value / Share | 0.0% | -8407721.4% | 100.0% | -236.6% | 102.0% | 353.3% | -238.8% | 907.2% | -89.9% | |
| Debt | 0.0% | -20.0% | -88.1% | 147.6% | -100.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | -100.0% | 6963537.5% | -56.7% | 206.0% | 33.5% | 94.0% | -96.0% | 2390.8% |
Valuation
P/E (TTM)8.26
P/S0.00
P/B2.64
10Y Low / Med / High1.01 / 309.56 / 1207.32
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.18
Graham Number
$2.39
Cash / Share
$0.12
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -202.81 | -3.50 | -235.92 | -195.93 | -54.81 | -61.43 | -73.75 | -0.80 | -0.88 | 8.26 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -176.44 | -0.00 | -208.72 | -62.01 | 1207.32 | 309.56 | -101.99 | 1.13 | 1.01 | 2.64 | |
| EV/EBITDA | -237.29 | -2131.67 | -278.49 | 8.04 | -54.80 | -65.07 | -76.44 | 0.02 | -2.44 | -0.24 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-14.48
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $132.5M | $178.6M | $0.00 |
| Net Income | -$4.5M | -$2.3M | -$2.8M |
| EPS | $-1.18 | $-0.60 | $-0.74 |
| # Analysts (EPS) | 1 | 1 | 1 |